Neovacs (France)

Recent papers from Neovacs (France)

1. The effect of nearby listings on house sale prices in Sydney: A spatio‐temporal regularization approachReal Estate Economics · 2026
2. A vaccine targeting human IgE induces long-term protection against anaphylaxis in humanized miceScience Translational Medicine · 2025
3. Pre-clinical evaluation of mRNA-lipid nanoparticles’ potency and toxicity: current practices and future directionsIn vitro models · 2025
4. SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic targetThe Medicine Forum · 2025
5. Animal Models of IgE AnaphylaxisBiology · 2023
6. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primatesBiomaterials · 2022
7. Therapeutic Potential of Anti-Interferon α Vaccination on SjS-Related Features in the MRL/lpr Autoimmune Mouse ModelFrontiers in Immunology · 2021
8. Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in miceNature Communications · 2021
9. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled studyAnnals of the Rheumatic Diseases · 2019
10. Microenvironment tailors nTreg structure and functionProceedings of the National Academy of Sciences · 2019
11. Different pre-implantation phenotypes of bovine blastocysts produced in vitroReproduction · 2018
12. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II studyLara D. Veeken · 2016
13. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infectionProceedings of the National Academy of Sciences · 2015
14. Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical TrialPLoS ONE · 2014
15. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapyJournal of Antimicrobial Chemotherapy · 2013
16. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adultsHuman Vaccines & Immunotherapeutics · 2013
17. Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoidArthritis & Rheumatism · 2012
18. A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older AdultsThe Journal of Infectious Diseases · 2012
19. IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cellsProceedings of the National Academy of Sciences · 2011
20. Induction of Strong HIV-1–Specific CD4+ T-Cell Responses Using an HIV-1 gp120/NefTat Vaccine Adjuvanted With AS02A in Antiretroviral-Treated HIV-1–Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes · 2011